A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
← catalyst calendarNCT06706817 · readout in 147 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Fortrea.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
181actual
Sites
41
Countries
Bulgaria, Canada, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-03 | actual | When the study began enrolling |
| Primary completion | 2027-01-13 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-13 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Rhinosinusitis With Nasal Polyps
Intervention
- Combination product: Tezepelumab — also filed as TEZSPIRE®
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in nasal congestion
measured Week 24
Change from baseline in sino-nasal symptoms
measured Week 24
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed